Systemic Lupus Erythematosus Treatment Market Growth Factors with Key Drivers Forecast From 2020-2026 | Industry Analysis By Key Players, And Upcoming Trends
SEATTLE, March 25, 2021, (PHARMIWEB) — Global Systemic Lupus Erythematosus (SLE) Treatment Market
Systemic Lupus Erythematosus (SLE) is chronic autoimmune disorder characterized by excess production of the antibodies that are known to attack the body’s vital organs and cells. Various symptoms associated with the disease include joint pain, swelling, rashes over face (butterfly rash) and other body area, severe fatigue, hair loss, anemia, and Raynaud’s phenomenon etc. SLE can also affect vital body organs such as heart, kidney, lungs, and behavioral changes. Exact causes of the disease is unknown, however, hereditary and environmental factors could be lead to SLE. There is no direct cure available for SLE, however, symptomatic treatment can be administered to lower or eliminate symptoms associated with disease. Major classes of drugs commonly used are antimalarial agents such as chlorquine and hydrochlorquine; topical steroid cream for rashes; NSAIDS for joint pain; and fever steroidal medication such as glucocorticoids through IV or oral route and immunosuppressive agents to lower immune response from the antibodies.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1540
Global Systemic Lupus Erythematosus (SLE) Treatment Market Dynamics
Rising incidence of SLE is one of the major factors driving the growth of the global SLE treatment market. According to a study published in the Expert Review of Clinical Immunology in 2017, the global incidence rate varied from about 0.3–23.7 per 100,000 individuals and the prevalence rates varied in the range from 6.5 to 178.0 per 100,000 people. The key companies operating in the global market are entering into collaborations for research and development of systemic lupus erythematosus, and this is expected to support the global market growth in the approaching years. For instance, in 2015, a genomic mapping company, 23andMe, Inc., collaborated with Pfizer, Inc. to study and understand the genetics of lupus thereby, to develop treatment for it. In 2012, Alliance for Lupus Research and Pfizer’s Centers for Therapeutic Innovation collaborated to discover new therapies for patients living with systemic lupus erythematosus. Increasing approvals for products for the treatment of SLE is another factor expected to aid in growth of the market. For instance, GlaxoSmithKline, in July 2017, received U.S.FDA approval for the subcutaneous form of its biologic drug belimumab for treatment of systemic lupus erythematosus. Clinical guidelines to include biologics in the treatment of systemic lupus erythematosus would further aid in market growth. Multidisciplinary group consisting international experts in various branches such as internal medicine, rheumatology, nephrology, dermatology, pediatrics, and cardiology published recommendations in journal Autoimmune Review in 2017, for the use of biologics in patients with systemic lupus erythematosus, according to which biologic drugs such as abatacept, rituximab, or tocilizumab can be used after evaluating patient profile. However, high costs associated with the treatment of systemic lupus erythematosus makes the treatment unaffordable, which is restraining factor for the global market growth.
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Systemic Lupus Erythematosus Treatment Market Research Report: https://bit.ly/39h3qci
Global Systemic Lupus Erythematosus (SLE) Treatment Market- Regional Insights
North America is expected to emerge as the most dominant market in the global SLE treatment market over the projected period, owing to the relatively higher prevalence of SLE in this region, as compared to that in other regions. According to a study published in the Rheumatology Journal in May 2017, the prevalence rate of SLE in North America was valued at 23.2 people per 1, 00,000 and 241 per 1, 00,000 people, respectively. Thus, the presence of well-known multinational companies in the region is another factor supporting the regional market growth. Leading players, such as GlaxoSmithKline, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb have a significant presence in this region.
The key players operating in the global systemic lupus erythematosus treatment market are GlaxoSmithKline Plc (GSK), F. Hoffmann-La Roche Ltd, Anthera Pharmaceuticals Inc., Bristol-Myers Squibb, Eli Lilly, Pfizer Limited, Merck KGaA, Immupharma Plc, Sanofi, Lycera Corporation, Aurinia Pharmaceuticals Inc., Mylan N.V., and Sandoz International GmbH.
These companies are deeply engaged in the development of novel therapies for the treatment of systemic lupus erythematosus, which would also aid in the global market growth. For instance, Immupharma Plc’s Lupozor completed its Phase 3 clinical trial in December 2017, which earlier was granted with the fast track status by the U.S. FDA. Atacicept from Merck Serono (German based Merck KGaA) completed phase 2 trial in February 2018. In March 2018, GlaxoSmithKline Plc started its Phase 3 clinical trial by combining belimumab (Benlysta) with rituximab for treating patients with systemic lupus erythematosus which is expected to provide efficient treatment for SLE than a single medicine.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/systemic-lupus-erythematosus-treatment-market-1540
Antimalarial is often used in mild SLE conditions, whereas, glucocorticoids and NSAIDS are commonly used in mild to moderate conditions. These are also preferred treatment in case of complications associated with SLE, where organs are damaging due to the disease. NSAIDS and immunosuppressive drugs segments hold a larger share in the market than other classes due to their proven efficacy in reducing symptoms and wider use in SLE conditions with organ complication. Biologics drugs segment are slowly gaining traction in the market with better outcomes and more patient compliance. Guidelines for use of biologic are also boosting confidence among physicians for adoption of biologics, as treatment for systemic lupus erythematosus.
By Treatment Type,
- Antimalarial Drugs
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Cytotoxic and Immunosuppressive Drugs
- Mycophenolate Mofetil
- B-Cell modulators
- T-Cell modulators
- Pro-inflammatory and cytokine inhibitors
By Route of Administration
By Distribution Channel
- Retail Pharmacy
- Online Pharmacy
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire